As at Jul 25, 2024, the UTHR stock has a PE ratio of 15.04. This is based on the current EPS of $22.36 and the stock price of $336.37 per share. An increase of 36% has been seen in the P/E ratio compared to the average of 11.0 of the last 4 quarters.
The mean historical PE ratio of UNITED THERAPEUTICS over the last ten years is 14.48. The current 15.04 PE ratio is 3.9% above the historical average. Over the past ten years, UTHR's PE ratio was at its highest in the Jun 2015 quarter at 47.14, with a price of $173.95 and an EPS of $3.69. The Jun 2016 quarter recorded the bottom point at 4.74, with a price of $105.92 and an EPS of $22.35.
Maximum annual increase: 76.93% in 2017
Maximum annual decrease: -48.36% in 2018
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 10.45 | -39.94% |
| 2022 | 17.4 | -14.62% |
| 2021 | 20.38 | 56.41% |
| 2020 | 13.03 | N/A |
| 2019 | N/A | N/A |
| 2018 | 8.04 | -48.36% |
| 2017 | 15.57 | 76.93% |
| 2016 | 8.8 | -20.36% |
| 2015 | 11.05 | -39.75% |
| 2014 | 18.34 | -43.4% |
Currently, UTHR's PE ratio is greater than its 3, 5 and 10-year historical averages.
UTHR's PE ratio is lower than its peer stocks LLY and GILD, but it is greater than BAX's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BAX Baxter International Inc | 6.79 | $18.1B |
| UTHR UNITED THERAPEUTICS Corp | 15.12 | $15B |
| CAH Cardinal Health Inc | 43.14 | $23.95B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| GILD Gilead Sciences Inc | 192.55 | $95.96B |
| TEVA Teva Pharmaceutical Industries Ltd | N/A | $19.37B |
| PFE Pfizer Inc | N/A | $174.36B |
| CYTK Cytokinetics Inc | N/A | $6.26B |
As of Jul 25, 2024, UTHR stock has a price to earnings ratio of 15.04.
The 3-year average PE ratio for UTHR stock is 14.18.
The 5-year average PE ratio for UTHR stock is 13.77.
Over the last ten years, the quarterly PE ratio reached a historic high of 47.14 in the Jun 2015 quarter.
UTHR's current price to earnings ratio is 3.9% above its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jul 25, 2024), UNITED THERAPEUTICS's stock price is $336.37. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $22.36. Therefore, UNITED THERAPEUTICS's P/E ratio for today is 15.04. PE RATIO(15.04) = STOCK PRICE($336.37) / TTM EPS($22.36)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.